Year of award: 2020
Mologic Ltd, United Kingdom
Liverpool School of Tropical Medicine, United Kingdom
Liverpool School of Tropical Medicine, United Kingdom
St George's, University of London, United Kingdom
Institut Pasteur de Dakar, Senegal
Rapid diagnostics have been identified by the WHO R&D Blueprint as a critical unmet need for the control of COVID-19 – particularly in the absence of a vaccine and proven antiviral agents. Our primary objective is to develop a low cost, high performance rapid test for the detection and exclusion of SARS-CoV-2, the causative virus of coronavirus disease 2019 (COVID-19).
The technology will be made available in line with the Global Access Policy for Gavi-eligible countries that are most vulnerable to onward transmission of COVID-19 and of limited detection due to insufficient laboratory capacity. The RDT will be appropriate for assembly and manufacture with multiple quality-assured partners to meet demand.